Trial · NCT03117140
Analgesia Duration of Dexamethasone, Buprenorphine, or Clonidine With Ropivacaine for Interscalene Nerve Block
NCT03117140, Phase 4, Completed, Melinda Seering; results first posted 2018-07-03
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Analgesia Duration of Dexamethasone, Buprenorphine, or Clonidine With Ropivacaine for Interscalene Nerve Block. Trials, record NCT03117140. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03117140
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Analgesia Duration of Dexamethasone, Buprenorphine, or Clonidine With Ropivacaine for Interscalene Nerve Block
- NCT number
- NCT03117140
- Status
- Completed
- Phases
- Phase 4
- Enrollment
- 160 participants, actual
- Lead sponsor
- Melinda Seering
- Conditions
- Anesthesia, Local
- Interventions
- Ropivacaine 0.75%, Ropivacaine 0.75% + 300 mcg Buprenorphine, Ropivacaine 0.75% + 75 mcg clonidine, Ropivacaine 0.75% + 8 mg dexamethasone
- First posted
- 2017-04-17
- Last updated
- 2018-07-03
- Results first posted
- 2018-07-03
Source ClinicalTrials.gov
Registered outcomes15
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Duration of Analgesia | 1-3 days post-operative | Patients are called 1-3 days post-operatively to assess when the analgesia of their nerve block wore off |
| Secondary | Block Set up Time | Day one | Patients are assessed from needle removal to when they are no longer able to feel cold on the blocked extremity |
| Secondary | Sensory Duration of Block | Day 1-3 | Patients are called 1-3 days post-operatively to assess when the sensory component of their nerve block wore off |
| Secondary | Patient Reporting Vomiting at Home | 1-3 days | Patients are called 1-3 days post-operatively to assess if they had any side effects of the adjuvants such as nausea, vomiting or itching. There blood pressure is looked at pre-op and compared to post-op. Any prolonged PACU (Post Anesthesia Care Unit) stay for sedation is recorded. |
| Secondary | Number of Patients Vomiting in the PACU (Post-Anesthesia Care Unit) | Post-op Day 0 (Baseline) | Vomiting in PACU (Post-Anesthesia Care Unit) for patients was looked at |
| Secondary | Number of Patients Reporting Nausea at Home | 1-3 days | Patients are called 1-3 days post-operatively to assess if they had any side effects of the adjuvants such as nausea, vomiting or itching. There blood pressure is looked at pre-op and compared to post-op. Any prolonged PACU (Post Anesthesia Care Unit) stay for sedation is recorded. |
| Secondary | Number of Patients Reporting Nausea in the PACU | Post-op day 0 (Baseline) | PACU (Post-Anesthesia Care Unit) assessment of nausea |
| Secondary | Motor Duration of Block | Day 1-3 | Patients are called 1-3 days post-operatively to assess when motor component of their nerve block wore off |
| Secondary | Number of Patients With Blood Pressure (BP) Changes in the PACU | Post-op Day 0 (baseline) | Blood pressure changes in PACU (Post-Anesthesia Care Unit) for patients was looked at |
| Secondary | Number of Patient With Blood Pressure Changes in the Second Stage Recovery Area | Post-op Day 0 (baseline) | Blood pressure changes in Second Stage Recovery Area for patients was looked at |
1 to 10 of 15Source ClinicalTrials.gov
See all 15 registered outcomesOutcomes15
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Duration of Analgesia | 1-3 days post-operative | minutes | MEDIAN | |
| SECONDARY | Block Set up Time | Day one | minutes | MEDIAN | |
| SECONDARY | Sensory Duration of Block | Day 1-3 | minutes | MEDIAN | |
| SECONDARY | Patient Reporting Vomiting at Home | 1-3 days | 1 patient in the Plain Ropivacaine group and the Ropivacaine and Buprenorphine group did not complete the survey about vomiting at home and therefore was not included in the analysis | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Patients Vomiting in the PACU (Post-Anesthesia Care Unit) | Post-op Day 0 (Baseline) | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Number of Patients Reporting Nausea at Home | 1-3 days | 1 patient in the Plain Ropivacaine group and the Ropivacaine and Buprenorphine group did not complete the survey about nausea at home and therefore was not included in the analysis | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Patients Reporting Nausea in the PACU | Post-op day 0 (Baseline) | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Motor Duration of Block | Day 1-3 | minutes | MEDIAN | |
| SECONDARY | Number of Patients With Blood Pressure (BP) Changes in the PACU | Post-op Day 0 (baseline) | 1 patient in Ropivacaine and Buprenorphine group did get data for the BP changes in the PACU for the study so therefore was not included in the analysis | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Patient With Blood Pressure Changes in the Second Stage Recovery Area | Post-op Day 0 (baseline) | 1 patient in Ropivacaine and Buprenorphine group did not have blood pressure data obtained in the second stage area so therefore was not included in the analysis | Participants | COUNT_OF_PARTICIPANTS |
1 to 10 of 15Source ClinicalTrials.gov
See all 15 outcomesResults by group68
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Duration of Analgesia | Plain Ropivacaine | 911 | Inter-Quartile Range 652 to 1300 | minutes | |
| Duration of Analgesia | Ropivacaine + Buprenorphine | 1026.5 | Inter-Quartile Range 756.5 to 1392.5 | minutes | |
| Duration of Analgesia | Ropivacaine + Clonidine | 1181 | Inter-Quartile Range 880.5 to 1528.5 | minutes | |
| Duration of Analgesia | Ropivacaine + Dexamethasone | 982 | Inter-Quartile Range 799 to 1270 | minutes | |
| Block Set up Time | Plain Ropivacaine | 6 | Inter-Quartile Range 3 to 9 | minutes | |
| Block Set up Time | Ropivacaine + Buprenorphine | 3 | Inter-Quartile Range 3 to 6 | minutes | |
| Block Set up Time | Ropivacaine + Clonidine | 6 | Inter-Quartile Range 3 to 6 | minutes | |
| Block Set up Time | Ropivacaine + Dexamethasone | 4.5 | Inter-Quartile Range 3 to 10.5 | minutes | |
| Sensory Duration of Block | Plain Ropivacaine | 923.5 | Inter-Quartile Range 652 to 1304 | minutes | |
| Sensory Duration of Block | Ropivacaine + Buprenorphine | 982 | Inter-Quartile Range 705 to 1189 | minutes |
1 to 10 of 68Source ClinicalTrials.gov
See all 68 results by groupParticipant flow12
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Plain Ropiviciane | 40 | |
| Overall Study | STARTED | Ropiviciane + Buprenorphine | 40 | |
| Overall Study | STARTED | Ropivicaine + Clonidine | 40 | |
| Overall Study | STARTED | Ropiviciane + Dexamethasone | 40 | |
| Overall Study | COMPLETED | Plain Ropiviciane | 40 | |
| Overall Study | COMPLETED | Ropiviciane + Buprenorphine | 40 | |
| Overall Study | COMPLETED | Ropivicaine + Clonidine | 40 | |
| Overall Study | COMPLETED | Ropiviciane + Dexamethasone | 40 | |
| Overall Study | NOT COMPLETED | Plain Ropiviciane | 0 | |
| Overall Study | NOT COMPLETED | Ropiviciane + Buprenorphine | 0 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 participant flowAdverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals12
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Plain Ropivacaine | 0 | 40 |
| Total, all-cause mortality | Ropivacaine + Buprenorphine | 0 | 40 |
| Total, all-cause mortality | Ropivacaine + Clonidine | 0 | 40 |
| Total, all-cause mortality | Ropivacaine + Dexamethasone | 0 | 40 |
| Total, other adverse events | Plain Ropivacaine | 0 | 40 |
| Total, other adverse events | Ropivacaine + Buprenorphine | 0 | 40 |
| Total, other adverse events | Ropivacaine + Clonidine | 0 | 40 |
| Total, other adverse events | Ropivacaine + Dexamethasone | 0 | 40 |
| Total, serious adverse events | Plain Ropivacaine | 0 | 40 |
| Total, serious adverse events | Ropivacaine + Buprenorphine | 0 | 40 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 adverse event totalsPapers33
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03117140
GET https://conductscience.org/api/trials/v1/NCT03117140/results?page=2